... received second-line immunotherapy after disease progression. The relationship between the expression level of SIRT7 by immunohistochemistry and clinicopathological characteristics, disease-free survival (DFS), overall survival (OS), and OS after progression (POS) was analyzed. Results: Over a mean follow...

..., quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2024 Adjuvant therapy Immunotherapy Renal cell carcinoma Real-world data...

... an anti-PD‐L1 antibody (22C3 pharmDx), which indicated positive IHC staining of PD-L1 expression (≥1%) (online suppl. Fig. 4). Due to lack of standard therapy, immunotherapy in combination with nab-paclitaxel chemotherapy was recommended to the patient. The administration of the immune checkpoint...

... closely associated with tumor immunotherapy and prognosis. The complex composition of the urological tumor microenvironment not only varies greatly in response to immunotherapy, but the prognostic value of TLSs in different urological tumors remains controversial. Summary: We searched PubMed, Web...

...) in metastatic urothelial carcinoma undergoing immunotherapy are sparse. Consequently, we performed a prospective clinical pilot study about HRQoL using the Functional Assessment of Cancer Therapy – Immune Checkpoint Modulator (FACT-ICM) questionnaire. Materials and Methods: Formally, this study is a prospective...

... and toxicity. Checkpoint inhibition First-line therapy Immunotherapy Metastatic renal-cell carcinoma 23 09 2021 15 12 2021 14 2 2022 © 2022 S. Karger AG, Basel 2022 Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may...

... premenopausal women treated with the vaccine experienced recurrence, indicating that Uromune® effectively prevented new recurrences of UTI for 88% of the premenopausal women [ 16 ]. The previously mentioned Spanish study comparing R-UTI patients treated with sublingual bacterial immunotherapy to those given...

... responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Urinary bladder neoplasms Immunotherapy Interleukin-2  Instillation Marker tumour The initial management of non-muscle-invasive bladder...

... affected by other genitourinary diseases were excluded. Non-muscle invasive bladder cancer Intravesical instillation Immunotherapy Compliance Toxicity Bacillus Calmette Guèrin © 2015 S. Karger AG, Basel Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part...

...Chong Xie; Guomin Wang Introduction: Gene-modified cell vaccines are now considered to be the best way to achieve immunotherapy for a variety of cancers including prostate cancer (PCa). XAGE-1b is a member of the cancer/testis antigen family which has demonstrated strong immunogenicity. We...

... at 1, 3 and 5 years in patients with non-muscle-invasive bladder cancer (NMIBC) who underwent a transurethral resection of bladder cancer following intravesical adjuvant chemotherapy or immunotherapy if indicated and to compare them with the European Organization for Research and Treatment of Cancer...

... with anti-Fas monoclonal antibody. These results suggest that selective COX-2 inhibitors in combination with immunotherapy may be useful in treating patients with RCC. Immunotherapy Kidney cancer Renal cell carcinoma Cyclooxygenase-2 Fas Apoptosis © 2010 S. Karger AG, Basel 2010 Copyright...

...S. Kleinknecht; K.-H. Bichler; W.L. Strohmaier Assessing the peripheral blood immune status, we had found evidence of immunosuppression in metastatic renal cell carcinoma. Since immunosuppression might interfere with the outcome of immunotherapy, it was submitted to further investigation...

... and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Bladder carcinoma Superficial Recurrent Immunotherapy Bacillus Calmette-Guérin Intradermal Intravesical Original...

... of the combination are emphasized in this report. The therapeutic efficacy of such a combination has yet to be determined and further clinical studies are warranted. Superficial bladder cancer Immunotherapy Intravesical therapy Bacillus Calmette-Guérin Epirubicin 19 04 1993 2 09 1993 3 2...

... subjective improvement for 2 months. However, during the 3rd month of treatment there was global deterioration which progressed further till his demise during the 4th month. The beneficial role, if any, of combined hormonal and immunotherapy in advanced prostatic carcinoma is discussed as also the natural...

... responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Superficial bladder cancer Toxicity Immunotherapy Bacillus Calmette-Guérin Intravesical therapy Clinical use Original Papers Urol Int 1990;45...

...T. Schärfe; S. Müller; H. Riedmiller; G.H. Jacobi; R. Hohenfellner 119 patients with stage-IV renal cell carcinoma were treated using immunotherapy with autologous tumor vaccine. The immunization was carried out at monthly intervals, the patients were restaged every 3 months using X-ray, ultrasound...

... and human urogenital cancers were also identified by the PAP study. Then, local immunotherapy with OK-432 was carried out in 38 patients with superficial bladder tumor and the tumors were eliminated in 23.7%. In 77.8% of the complete response and in 10.3% of the no change, the tumor tissues demonstrated...

... in 10 (21.7%) patients at the end of the BCG cycles. Radical cystectomy was done in 10 patients. The tumor-free survival rate of all patients including those who underwent cystectomy is 84.8% (39 of 46) with a median follow-up of 61 (range 39–118) months. Conclusion: Adjuvant immunotherapy with BCG...